<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-X6973WOC</identifier><date>1997</date><creator>Štabuc, Borut</creator><relation>documents/doc/X/URN_NBN_SI_doc-X6973WOC_001.pdf</relation><relation>documents/doc/X/URN_NBN_SI_doc-X6973WOC_001.txt</relation><format format_type="type">article</format><format format_type="extent">Str. 84-90</format><identifier identifier_type="COBISSID_HOST">7727833</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-X6973WOC</identifier><language>slv</language><publisher>Glaxo Wellcome</publisher><source>Onkološki vikend</source><rights>BY-NC-ND</rights><subject language_type_id="eng">Combined modality therapy</subject><subject language_type_id="eng">Drug therapy</subject><subject language_type_id="eng">Esophageal neoplasms</subject><title>Kemoterapija raka požiralnika</title></Record>